• Adolor Corp., of Exton, Pa., reported top-line data from two randomized, double-blind, placebo-controlled Phase II trials of ADL5945 for opioid-induced constipation. When dosed twice daily, high-dose ADL5945 significantly increased the weekly number of spontaneous bowel movements vs. placebo (3.4 SBMs vs. 1.4 SBMs; p = 0.0003). The difference for the low-dose group (2 SBMs) was not significant. High-dose ADL5945 also significantly improved SBMs with once-daily dosing. The drug, a peripherally acting mu opioid receptor antagonist, was well tolerated.

• Glenmark Pharmaceuticals Ltd., of Mumbai, India, initiated two Phase IIb dose-ranging trials of Revamilast (GRC 4039) for asthma and rheumatoid arthritis. Revamilast is an oral phosphodiesterase 4 inhibitor.